The ASIP chip is globally protected by more than 175 patents and production standards.

AlphaSIP’s technology, resulting from the comprehensive combination of Spanish researchers’ know-how and Harvard’s technology, is an important breakthrough in the IVD market. The technology’s miniaturizing and integration capability fosters diverse personalized applications.

The biomedical applications of AlphaSIP’s technology are focused on one main research area: haemostasis and coagulation (Oral Anticoagulant Treatment monitoring).

There are certain applications in this field, such as Profound Venous Thrombosis, embolisms and myocardial infarctions, which currently don’t benefit from the in-home monitoring that other illnesses such as diabetes do. These have very interesting market opportunities due to the outburst of these conditions in society.